Janssen offer Nordic life science innovators and entrepreneurs the opportunity to develop their early-stage research and development projects in a global environment.
In the past ten years, Janssen have brought more differentiated pharmaceutical products to patients than any other company. Now, through Johnson & Johnson Innovation, we are offering our expertise and experience to the next generation of medical innovators.
Johnson & Johnson Innovation is a global network of innovation hubs located in London, California, Boston and Asia Pacific. At Johnson & Johnson Innovation, we bring together our expertise in R&D, business development and funding to provide customized support to exciting early-stage research projects around the world.
The aim of Johnson & Johnson Innovation is to develop transformational healthcare innovations together with regional innovation ecosystems. Europe is an important region due to its multifaceted nature and the region is supported by local liaisons in strategically important countries.
“By launching a hub in the Nordics, we can help scientists and innovators in the region design the right experiments, develop their business model, and get the funding needed to take the next step. My job is to work closely with universities, incubators, and the life science community to bring forward innovative therapies, diagnostics, and devices that will transform the future of patients”, says Anna Gran, External Innovation Liaison in the Nordics.
Johnson & Johnson Innovation is looking for opportunities in our therapeutic areas of focus in our Pharmaceutical sector as well as opportunities in medical devices and consumer businesses.
Today, Johnson & Johnson Innovation has 200+ external collaborations with academia, start-up companies, and other life science organizations.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC is working to accelerate scientific innovation at all stages of development worldwide to deliver cutting-edge solutions that solve unmet needs for patients. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to the broad resources of the Johnson & Johnson Family of Companies across the Pharmaceutical, Medical Devices and Consumer healthcare segments. This includes access to dealmakers, through the innovation centers located in global life science hot spots and Johnson & Johnson Innovation – Janssen Business Development; venture investment, through Johnson & Johnson Innovation – JJDC; company incubation, through Johnson & Johnson Innovation, JLABS; as well as R&D, manufacturing and commercialization expertise across all three segments. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
Janssen is a pharmaceutical company of Johnson & Johnson. Janssen provides medicines for an array of therapeutic areas, including: neuroscience (e.g. schizophrenia, dementia and pain), oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), infectious disease (e.g. HIV/AIDS, Hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). For more information, visit www.janssen.se.
Anna Gran, PhD MBA, is currently holding a dual position with Janssen Nordics and Johnson & Johnson Innovation as External Innovation Liaison, Nordics. She has 9 years of experience from biomedical research as well as experience from launching new cancer medicines in the Nordic region. She is currently responsible for forging partnerships between Johnson & Johnson and Nordic life science organizations and companies, in order to accelerate early-stage development of innovative healthcare products.